Merck's Q1 2019 transcript highlights strong financial performance, with robust growth in key products such as Keytruda and Gardasil. The company reported exceptional growth rates in oncology and international markets, particularly China, bolstered by new product launches and strategic international expansion. However, management's update on robust earnings and raised guidance suggests strong momentum, potentially invigorating investor confidence and leading to positive short-term stock performance.

[1]